GLP-1
PulseAugur coverage of GLP-1 — every cluster mentioning GLP-1 across labs, papers, and developer communities, ranked by signal.
- instance of Ozempic 90%
- instance of Wegovy 90%
- instance of semaglutide 90%
- developed by Ozempic 90%
- affiliated with Ozempic 70%
- instance of tirzepatide 70%
- developed by Eli Lilly and Company 70%
- used by Ozempic 70%
- developed by Novo Nordisk 70%
- used by Centers for Medicare and Medicaid Services 70%
- invested in The Cigna Group 70%
- competes with Wegovy 60%
9 day(s) with sentiment data
-
GLPcompare launches public API for GLP-1 cash prices
GLPcompare has launched a free, public Model Context Protocol (MCP) server to provide AI assistants with access to US GLP-1 cash prices. This server, accessible via a read-only HTTP endpoint, offers real-time pricing da…
-
Eating disorders surge 71% as experts warn GLP-1 drugs may worsen the crisis
A recent report indicates a significant increase in eating disorders, with anorexia nervosa and bulimia nervosa incidence rising by 71% between 1990 and 2023. Experts are concerned that popular GLP-1 weight-loss drugs m…
-
GLP-1 Drugs Poised to Reshape US Healthcare and Public Health
GLP-1 drugs are poised to significantly alter the landscape of healthcare and public health in the United States, according to a public health expert. These medications are expected to bring about substantial changes in…
-
Steve Jobs' son sees GLP-1 drugs as key to fighting cancer
Reed Jobs, son of Steve Jobs, believes that GLP-1 drugs, known for their impact on obesity, could also play a significant role in fighting cancer. He highlighted that obesity is a risk factor for a substantial percentag…
-
Gen Z in South Korea lead GLP-1 slimming drug use: survey
A recent survey indicates that approximately 16.5% of South Korean Gen Z individuals used GLP-1 slimming drugs in 2025, a significantly higher rate than other age groups. The overall usage across all surveyed age bracke…
-
LLM agent AskGLP1 maps GLP-1 patient experiences to knowledge graph
Researchers have developed AskGLP1, an LLM-powered agent designed to extract and structure information about GLP-1 medication experiences from online patient narratives. The system processes millions of posts from platf…
-
Researchers Regrow Knee Cartilage in Mice, Advancing to Human Trials
Researchers have successfully regrew knee cartilage in mice, a significant step towards potential treatments for joint degeneration. This breakthrough is now advancing to clinical trials, offering hope for new therapies…
-
GLP-1 Medications Reshape Travel Industry: Hotels, Menus, and Wellness Adapt
The rise of GLP-1 medications like Ozempic and Wegovy is influencing the travel industry, prompting changes in hotel services and offerings. Travelers using these drugs are seeking specific amenities such as in-room med…
-
GLP-1 drugs may slow aging; Elon Musk settles voter giveaway lawsuits
A new study from the University of California, San Francisco suggests that GLP-1, a popular weight-loss drug, may slow biological aging. Separately, Elon Musk has settled lawsuits related to his promise to give away $1 …
-
GLP-1 drugs poised to outpace AI in impact and revenue
GLP-1 drugs are projected to have a more significant impact than artificial intelligence over the next two years, with sales expected to surpass generative AI revenue by the end of 2025. While initial costs were high, p…
-
GLP-1 drugs drive US obesity rate decline amid patent competition
The obesity rate in the United States has begun to decline, largely attributed to the increasing availability and affordability of GLP-1 weight-loss medications like Wegovy. These drugs, initially developed from a pepti…
-
MIT Tech Review: AI refusal failures, GLP-1 side effects, and green data centers
MIT Technology Review's "The Download" newsletter highlights critical concerns regarding AI's refusal capabilities, noting that while models are trained to decline harmful requests, these refusals can fail with potentia…
-
AI chatbots exhibit 'emotions' while leaders deny control; OpenAI releases math proofs
Scientists have explored the emotional states of AI chatbots, finding that inducing 'sadness' or 'fear' and then 'calming' them can lead to surprisingly useful outcomes. Separately, leaders of major AI companies are rep…
-
GLP-1 weight-loss drugs linked to younger biological age, side effects under scrutiny
GLP-1 weight-loss drugs are showing potential benefits in reducing biological age, with users appearing two to three years younger than placebo groups according to research from Eli Lilly and Novo Nordisk. Despite wides…
-
Ozempic, Wegovy linked to lower Alzheimer's risk in new study
A new study published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association suggests a link between semaglutide, the active ingredient in Ozempic and Wegovy, and a reduced risk of Alzheimer's disease. Re…
-
Weight-loss drugs may slow biological aging, studies suggest
Weight-loss drugs like GLP-1s from Eli Lilly and Novo Nordisk are showing potential to slow biological aging, according to molecular aging clocks. These drugs, which stimulate appetite suppression, have demonstrated a r…
-
McDonald's adjusts menus for GLP-1 drug users
McDonald's is adapting its menu to cater to customers using GLP-1 weight-loss medications. The fast-food chain is reportedly reducing portion sizes and increasing protein content in its offerings. A medical professional…
-
Unrelated News: Mastodon and Ozempic Side Effects
This cluster contains two unrelated news items. The first discusses Mastodon, a decentralized social media platform, in an article titled "Hardly Promethean." The second item reports on potential side effects of Ozempic…
-
Obesity expert warns against compounded GLP-1s, citing safety risks
An obesity expert criticizes the widespread practice of compounding GLP-1 medications, arguing that many online sellers exploit regulatory loopholes for profit rather than genuine medical necessity. The expert emphasize…
-
New benchmark reveals hindsight bias in clinical LLM reasoning
Researchers have developed a new benchmark to measure hindsight bias in large language models when reasoning about clinical temporal data. The benchmark, comprising 171 case reports from PubMed Central, evaluates how mo…